頭孢菌素藥物市場：按頭孢菌素生成、藥物給藥、處方類型和用途分類 - 2023-2030 年全球預測

預計2023年全球頭孢菌素市場將達到113.7億美元，複合年成長率為6.64%，大幅成長，2030年將達到178.6億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球頭孢菌素市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對整體收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解自家公司在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球頭孢菌素市場規模及預測如何？

2.在預測期內，COVID-19對全球頭孢菌素藥物市場的阻礙因素與影響為何？

3. 在預測期內，全球頭孢菌素市場需要投資哪些產品/細分市場/用途/領域？

4.全球頭孢菌素市場的競爭策略為何？

5.全球頭孢菌素市場的技術趨勢與法律規範如何？

6.全球頭孢菌素市場主要供應商的市佔率是多少？

7. 哪些型態和策略措施被認為適合進入頭孢菌素全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 細菌感染疾病增加，如皮膚和尿道感染
    • 持續關注研發和臨床試驗
    • 聯合治療的廣泛應用
  • 抑制因素
    • 與頭孢菌素相關的副作用
  • 機會
    • 製藥公司和組織加大投資，加速抗生素開發
    • 修訂支持抗生素的政府法規
  • 任務
    • 人們意識的限制與農村邊遠地區供需失衡
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 頭孢菌素藥品市場：以頭孢菌素世代分類

• 介紹
• 第五代
• 第一代
• 第四代
• 第二代
• 第三代

第7章 頭孢菌素市場：依藥品給藥

• 介紹
• 注射
• 口服

第8章 頭孢菌素市場：依處方類型

• 介紹
• 非處方藥物
• 處方藥

第9章 頭孢菌素市場：依用途

• 介紹
• 耳部感染疾病
• 呼吸道感染疾病
• 皮膚感染疾病
• 尿道感染

第10章 美洲頭孢菌素市場

• 介紹
• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第11章亞太地區頭孢菌素市場

• 介紹
• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第12章歐洲、中東和非洲頭孢菌素市場

• 介紹
• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第13章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第14章上市公司名單

第15章附錄

• 討論指南
• 關於許可證和定價

The Global Cephalosporin Drugs Market is forecasted to grow significantly, with a projected USD 11.37 billion in 2023 at a CAGR of 6.64% and expected to reach a staggering USD 17.86 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cephalosporin Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cephalosporin Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Generation of Cephalosporin, market is studied across Fifth-Generation, First-Generation, Fourth-Generation, Second-Generation, and Third-Generation. The First-Generation is projected to witness significant market share during forecast period.

Based on Drug Administration, market is studied across Injection and Oral. The Injection is projected to witness significant market share during forecast period.

Based on Prescription Type, market is studied across OTC Drugs and Prescription Drugs. The Prescription Drugs is projected to witness significant market share during forecast period.

Based on Application, market is studied across Ear Infection, Respiratory Tract Infection, Skin Infection, and Urinary Tract Infection. The Ear Infection is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cephalosporin Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cephalosporin Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cephalosporin Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cephalosporin Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cephalosporin Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cephalosporin Drugs Market?

6. What is the market share of the leading vendors in the Global Cephalosporin Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cephalosporin Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Cephalosporin Drugs Market, by Generation of Cephalosporin, 2022 vs 2030
• 4.3. Cephalosporin Drugs Market, by Drug Administration, 2022 vs 2030
• 4.4. Cephalosporin Drugs Market, by Prescription Type, 2022 vs 2030
• 4.5. Cephalosporin Drugs Market, by Application, 2022 vs 2030
• 4.6. Cephalosporin Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing cases of bacterial infection such as skin and UTIs
    • 5.1.1.2. Continuous focus on R&D and clinical trials
    • 5.1.1.3. Widespread application of a combination therapy
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects related to cephalosporins drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investment by pharmaceutical companies & associations to boost the antibiotic drug development
    • 5.1.3.2. Revised government regulation in favor of antibiotic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Limited consciousness among the people and unbalanced demand & supply in rural or remote areas
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Cephalosporin Drugs Market, by Generation of Cephalosporin

• 6.1. Introduction
• 6.2. Fifth-Generation
• 6.3. First-Generation
• 6.4. Fourth-Generation
• 6.5. Second-Generation
• 6.6. Third-Generation

7. Cephalosporin Drugs Market, by Drug Administration

• 7.1. Introduction
• 7.2. Injection
• 7.3. Oral

8. Cephalosporin Drugs Market, by Prescription Type

• 8.1. Introduction
• 8.2. OTC Drugs
• 8.3. Prescription Drugs

9. Cephalosporin Drugs Market, by Application

• 9.1. Introduction
• 9.2. Ear Infection
• 9.3. Respiratory Tract Infection
• 9.4. Skin Infection
• 9.5. Urinary Tract Infection

10. Americas Cephalosporin Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cephalosporin Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cephalosporin Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. CEPHALOSPORIN DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CEPHALOSPORIN DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2022 VS 2030 (%)
• FIGURE 5. CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 6. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2022 VS 2030 (%)
• FIGURE 7. CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 8. CEPHALOSPORIN DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. CEPHALOSPORIN DRUGS MARKET DYNAMICS
• FIGURE 10. CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CEPHALOSPORIN DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CEPHALOSPORIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 5. CEPHALOSPORIN DRUGS MARKET SIZE, BY FIFTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CEPHALOSPORIN DRUGS MARKET SIZE, BY FIRST-GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CEPHALOSPORIN DRUGS MARKET SIZE, BY FOURTH-GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CEPHALOSPORIN DRUGS MARKET SIZE, BY SECOND-GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CEPHALOSPORIN DRUGS MARKET SIZE, BY THIRD-GENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 11. CEPHALOSPORIN DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CEPHALOSPORIN DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 14. CEPHALOSPORIN DRUGS MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. CEPHALOSPORIN DRUGS MARKET SIZE, BY EAR INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CEPHALOSPORIN DRUGS MARKET SIZE, BY RESPIRATORY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CEPHALOSPORIN DRUGS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. CEPHALOSPORIN DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 57. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 61. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 130. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 146. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 150. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY GENERATION OF CEPHALOSPORIN, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CEPHALOSPORIN DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. CEPHALOSPORIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 190. CEPHALOSPORIN DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 191. CEPHALOSPORIN DRUGS MARKET LICENSE & PRICING